Navigation Links
ThromboGenics N.V.: Business Update
Date:11/6/2008

and early efficacy data on the product.

The deal with Roche was a key element in ThromboGenics' corporate strategy, and has allowed the Company to focus on developing the other attractive products in its pipeline, particularly its lead product, microplasmin. The upfront payment from Roche has also provided a significant portion of the funds needed for the microplasmin Phase III program, which will evaluate the drug in a number of back of the eye disease indications.

TB-402 (Anti-Factor VIII) - A Unique, Long-acting Anti-coagulant

ThromboGenics is developing TB-402 in collaboration with BioInvent International. TB-402 is a novel human antibody which partially blocks Factor VIII, an essential blood clotting factor. TB-402 is being developed as an anticoagulant for the treatment and prevention of deep vein thrombosis (DVT) and atrial fibrillation. It is anticipated that TB-402 will be a novel, safe, and affordable anticoagulant, providing extended activity with a single dose, with ease of administration and compliance superior to alternative anticoagulants.

The Phase I interaction studies, which were successfully completed in the second quarter of 2008, have shown that TB-402 has the potential to be a safe and well controlled treatment for diseases where the prevention of blood clots is imperative. As a result of the encouraging results from these studies, TB-402 is expected to begin its Phase II clinical development by the end of 2008.

ThromboGenics will provide a further update when the Company reports its 2008 Full Year Results on 12th March, 2009.
For further information please contact:

ThromboGenics:

Patrik De Haes, CEO, Tel : +32-16-75-13-10,

patrik.dehaes@thrombogenics.com

Chris Buyse, CFO, Tel : +32-16-75-13-10,


'/>"/>

SOURCE ThromboGenics NV
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. ThromboGenics Announces Half Year Results 2008
2. ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
3. ThromboGenics Announces Private Investors Acquire 8% Stake in the Company
4. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
5. ThromboGenics N.V. - Business Update
6. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
7. ThromboGenics Announces 2007 Full Year Results
8. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
9. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
10. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
11. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... , May 23, 2013 VG ... strategic alliance with DAK Renewable Research to conduct ... oil yield. VG Energy is a majority owned ... VGLS). VG Energy,s exclusively licensed compound ... the oil yield in plants, possessing a wide ...
(Date:5/23/2013)... Pa. , May 23, 2013 ... research and advisory firms for specialized biopharmaceutical issues, ... hepatologists, and infectious disease specialists reported that in ... patients (e.g., intentionally delaying treatment) in anticipation of ... than six months ago, when only 6 percent ...
(Date:5/23/2013)... , May 23, 2013 Northwest Biotherapeutics ... company developing DCVax ® personalized immune therapies for ... its exhibit at this year,s American Society Of Clinical ... to highlight its leadership role in immune therapy.  ... ASCO annual meeting is the pre-eminent conference focused on ...
(Date:5/23/2013)... 23, 2013  Verenium Corporation (Nasdaq: VRNM ... development and commercialization of high-performance enzymes, today announced that ... will present at two upcoming conferences. (Logo: ... at the Second Annual Marcum LLP Microcap Conference on ... in New York City.  The presentation is scheduled to ...
Breaking Biology Technology:VG Energy Enters into a Strategic Alliance with DAK Renewable Research for LipidMax Field Trials 2VG Energy Enters into a Strategic Alliance with DAK Renewable Research for LipidMax Field Trials 3The Majority of Physicians that Treat Hepatitis C Virus (HCV) Have Begun "Warehousing" and Preparing Their HCV Patients for the Next Generation of HCV Treatments 2The Majority of Physicians that Treat Hepatitis C Virus (HCV) Have Begun "Warehousing" and Preparing Their HCV Patients for the Next Generation of HCV Treatments 3NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 2NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 3Verenium To Present At Two Upcoming Conferences 2Verenium To Present At Two Upcoming Conferences 3
... Pier Pharmaceuticals Inc.(formerly known as Steady Sleep Rx ... treatment of sleep related breathing disorders (SRBDs), announced today ... CEO & President and his election to the Board ... Letendre will be responsible for spearheading the clinical, regulatory, ...
... Nanotecnologia (ICN), in Barcelona, has demonstrated a device that induces ... in developing the spin computers of the future. The results ... Science. The authors are Marius V. Costache and Sergio O. ... and Engineering of Nanodevices Group at ICN. Spintronics is ...
... 2010 The new biotechnology curriculum at Bunker Hill ... state to win a Silver endorsement from the new ... the College,s program acknowledges that it is successfully training ... state to keep a competitive edge. To ...
Cached Biology Technology:Pier Pharmaceuticals Names Peter Letendre as Chief Executive Officer, President and Director 2A 'spin ratchet': A new electronic structure for generating spin current 2Bunker Hill Community College Wins Major Endorsement for Biotechnology Courses 2
(Date:5/24/2013)... In the search for medication against Alzheimer,s disease, scientists have ... break down Amyloid beta (A-beta). After all, it is the ... brains of Alzheimer,s patients. Starting point for the formation of ... were the first to unravel the function of APPL ... healthy fruit flies. , Alessia Soldano (VIB/KU Leuven): "We ...
(Date:5/23/2013)... Northwest National Laboratory honored more than 165 staff ... property at PNNL,s annual Intellectual Property Commercialization Recognition ... of Energy national laboratory named materials scientist Jun ... developing battery materials that can store large amounts ... and reduce the time it takes to charge ...
(Date:5/23/2013)... of genomic DNA around nucleosomes in the cell ... team of Ludwig-Maximilians-Universitaet (LMU) in Munich now describes ... locally displaced from nucleosomes for transcription. , In ... the cell nucleus, wrapped around disk-shaped particles called ... different histone proteins and accommodating two loops of ...
Breaking Biology News(10 mins):A new strategy required in the search for Alzheimer's drugs? 2PNNL staff recognized for scientific accomplishments, moving technologies into the marketplace 2Biochemistry: Unspooling DNA from nucleosomal disks 2
... A new study has found that protein and not ... and burning calories. The research, published in the ... , has implications for understanding obesity and sleep disorders. ... which secrete a stimulant called orexin/hypocretin in the brain. ...
... that fuel is present in all vegetative matter that ... day grow their own fuel. Last year, global biofuel ... for 2.7% of the world,s transportation fuel. Bioethanol, a ... food crops such as corn and sugarcane. However, technologies ...
... extinction is a complicated task, especially for species that migrate ... Georgia and Tulane University have developed a mathematical model that ... the early online edition of the Royal Society journal ... lot of species, we don,t know very much about their ...
Cached Biology News:3 p.m. slump? Why a sugar rush may not be the answer 2Toward more cost-effective production of biofuels from plant lignocellulosic biomass 2New model more accurately describes migratory animals' extinction risk 2
Mouse monoclonal antibody raised against a full length recombinant SLC25A11. NCBI Entrez Gene ID = SLC25A11...
... raised against a partial recombinant ... TOPORS (NP_005793, 98 a.a. ... protein with GST tag. ... NM_005802 Protein ...
Mouse monoclonal antibody raised against a full length recombinant SNAPC5. NCBI Entrez Gene ID = SNAPC5...
... antibody raised against a partial recombinant NFKBIB. ... ~ 145 a.a) partial recombinant protein with GST ... Accession: BC015528 ... OMIM: 604495, GeneID: ...
Biology Products: